[Radiation dose intensification for glioblastoma]

Cancer Radiother. 2022 Oct;26(6-7):894-898. doi: 10.1016/j.canrad.2022.07.007. Epub 2022 Sep 6.
[Article in French]


Glioblastoma is the most common brain tumor in adults; its treatment includes surgical excision or biopsy followed by radio-chemotherapy. Even if radiotherapy increases the survival of all patients regardless of their age or their general condition, there are always sources of radioresistance, where relapses occur and therefore treatment fails. Indeed, these foci result in a local relapse, which is observed in 95% of cases in the irradiation fields. We will describe here the current approaches to overcome this radioresistance by dose escalation, without or with guidance by metabolic and functional imaging (dose-painting). We will detail several prospective trials including the French phase III trial, SPECTRO-GLIO, randomizing the use of an integrated boost guided by spectrometric magnetic resonance imaging and similar trials developed across the Atlantic. We will also discuss approaches using different PET markers as well as diffusion or perfusion magnetic resonance imaging.

Keywords: Clinical trial; Essais cliniques; Glioblastom; Glioblastome; Imagerie spectroscopique de résonance magnétique; Magnetic resonance qpectroscopic imaging; PET; Radiation oncology; Radiothérapie; TEP.

Publication types

  • Review

MeSH terms

  • Adult
  • Brain Neoplasms* / diagnostic imaging
  • Brain Neoplasms* / radiotherapy
  • Glioblastoma* / diagnostic imaging
  • Glioblastoma* / radiotherapy
  • Humans
  • Neoplasm Recurrence, Local
  • Prospective Studies
  • Radiation Dosage